» Articles » PMID: 26050923

Long-term Mortality Among Women with Epithelial Ovarian Cancer

Overview
Journal Gynecol Oncol
Date 2015 Jun 9
PMID 26050923
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Patients with solid tumors are at greatest risk for dying from their cancers in the five years following diagnosis. For most malignancies, deaths from other chronic diseases begin to exceed those from cancer at some point. As little is known about the causes of death among long-term survivors of ovarian cancer, we examined causes of death by years from diagnosis.

Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women diagnosed with ovarian cancer between 1988 and 2012. We compared causes of death by stage, age, and interval time after diagnosis.

Results: A total of 67,385 women were identified. For stage I neoplasms, 13.6% (CI, 13.0-14.2%) died from ovarian cancer, 4.2% (CI, 3.8-4.5%) from cardiovascular disease, 3.6% (CI, 3.3-3.9%) from other causes and 2.6% (CI, 2.4-2.9%) from other tumors; ovarian cancer was the leading cause of death until 7 years after diagnosis after which time deaths are more frequently due to other causes. For those with stage III-IV tumors, 67.8% (CI, 67.3-68.2%) died from ovarian cancer, 2.8% (CI, 2.6-2.9%) from other causes, 2.3% (CI, 2.2-2.4%) from cardiovascular disease and 1.9% (CI, 1.7-2.0%) from other cancers; ovarian cancer was the most frequent cause of death in years 1-15 after which time deaths were more commonly due to other causes.

Conclusions: The probability of dying from ovarian cancer decreases with time. Ovarian cancer remains the most common cause of death for 15 years after diagnosis in women with stage III-IV tumors.

Citing Articles

Size distribution of extracellular vesicles in pretreatment ascites and plasma is correlated with primary treatment outcome in advanced high-grade serous carcinoma.

Herzog M, Verdenik I, Kobal B, cerne K Sci Rep. 2025; 15(1):4500.

PMID: 39915670 PMC: 11802836. DOI: 10.1038/s41598-025-88707-9.


Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma.

Herzog M, Verdenik I, Kobal B, cerne K Int J Mol Sci. 2024; 25(12).

PMID: 38928484 PMC: 11204144. DOI: 10.3390/ijms25126780.


Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer.

Maehana T, Kawaguchi R, Nishikawa K, Kawahara N, Yamada Y, Kimura F Oncol Lett. 2024; 28(1):302.

PMID: 38774455 PMC: 11106690. DOI: 10.3892/ol.2024.14435.


High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.

Kohn P, Lalos A, Posabella A, Wilhelm A, Tampakis A, Caner E J Cancer Res Clin Oncol. 2023; 149(20):17943-17955.

PMID: 37966614 PMC: 10725329. DOI: 10.1007/s00432-023-05466-8.


The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients.

Kawahara N, Yamanaka S, Sugimoto S, Kamibayashi J, Nishikawa K, Kawaguchi R Cancers (Basel). 2023; 15(20).

PMID: 37894429 PMC: 10605019. DOI: 10.3390/cancers15205062.


References
1.
Prat J . Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2013; 124(1):1-5. DOI: 10.1016/j.ijgo.2013.10.001. View

2.
Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W . Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S161-92. DOI: 10.1016/S0020-7292(06)60033-7. View

3.
Youn P, Milano M, Constine L, Travis L . Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer. 2014; 120(15):2334-42. DOI: 10.1002/cncr.28733. View

4.
Kurta M, Edwards R, Moysich K, McDonough K, Bertolet M, Weissfeld J . Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014; 32(36):4102-12. PMC: 4265120. DOI: 10.1200/JCO.2014.55.1713. View

5.
Mertens A, Yong J, Dietz A, Kreiter E, Yasui Y, Bleyer A . Conditional survival in pediatric malignancies: analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program. Cancer. 2015; 121(7):1108-17. PMC: 4368489. DOI: 10.1002/cncr.29170. View